Metastasis inhibition of different tumor types by purified laminin fragments and a heparin-binding fragment of fibronectin

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


Tumor cell metastasis is a complex process that depends in part on tumor cell adhesion to components of basement membranes and the extracellular matrix. Previous studies have indicated that the experimental metastasis of murine melanoma cells can be inhibited by ex vivo pretreatment of cells with purified adhesion-promoting fragments of laminin or the synthetic peptide arginyl-glycyl-aspartyl-serine (RGDS) prior to tail vein injection. This study extended the earlier reports to demonstrate that adhesion-promoting fragments of laminin and fibronectin can inhibit the metastasis of a tumor of different histologic origin, such as murine fibrosarcoma cells. Furthermore, ex vivo pretreatment of cells with a purified 33-kDa heparin-binding fragment of fibronectin, which promotes tumor cell adhesion by an RGDS-independent mechanism, was effective at inhibiting experimental melanoma and fibrosarcoma pulmonary metastases. The survival rate of animals receiving tumor cells pretreated with this fragment was significantly enhanced relative to control groups. As with previous studies, the mechanism of inhibition appeared to involve an increased clearance rate of tumor cells from the pulmonary microcirculation. These results suggest a role for cell surface proteoglycans in the adhesion and metastasis of certain malignant neoplasms. Furthermore, this study emphasizes the complexity of tumor metastasis and suggests that multiple strategies may be developed to inhibit hematogenous metastasis formation.

Original languageEnglish (US)
Pages (from-to)108-116
Number of pages9
JournalJournal of the National Cancer Institute
Issue number2
StatePublished - Mar 16 1988

Bibliographical note

Funding Information:
1 Received May 26, 1987; accepted September 14, 1987. 2 Supported by Public Health Service grants CA-29995, CA-21463, CA-39510, CA-43924, and NRSA F32-CA-0865 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services; by the Viking's Children Fund (D698-5974); by the Minnesota Medical Foundation (MMF/CRF-94-87X by grants from the Leukemia Task Force; and by grant SMF 492-86 from the Minnesota Medical Foundation. A. P. N. Skubitz is the recipient of American Cancer Society fellowship PF#-2885. 3 University of Minnesota, Box 609, Mayo Memorial Building, Department of Laboratory Medicine and Pathology, Minneapolis, MN 55455. 4 Recipient of a Pardee Foundation Professorship in Cancer Biology. 5 The authors are grateful to Mr. Scott Hagen and Mr. John Mendiola for technical assistance and to Ms. Pat Hansen for assistance in performing the experimental metastasis assays. The expert assistance of Ms. Carol El-Ghandour in preparation of the manuscript is gratefully acknowledged.


Dive into the research topics of 'Metastasis inhibition of different tumor types by purified laminin fragments and a heparin-binding fragment of fibronectin'. Together they form a unique fingerprint.

Cite this